GlassScriptPhysician profile
Shannon Decker
NPI 1003469925
$2,916.89
in general payments reported to CMS, 2019-2025
24 companies · $284 in 2025
The $284 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $291 · 2022: $756 · 2023: $734 · 2024: $852 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,870.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,869.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $621.68 | 2021-2024 | Xarelto |
| Amgen INC. | $307.66 | 2022-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $242.77 | 2022-2025 | Jardiance |
| Abiomed | $232.43 | 2023-2024 | Impella |
| Novartis Pharmaceuticals Corporation | $190.47 | 2022-2024 | |
| Boston Scientific Corporation | $179.28 | 2022-2025 | Watchman Flx |
| Edwards Lifesciences Corporation | $140.64 | 2022 | |
| Esperion Therapeutics, INC. | $125.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $113.94 | 2021-2024 | Brilinta |
| Abbott Laboratories | $104.99 | 2023 | Cardiomems |
| Merck Sharp & Dohme LLC | $94.06 | 2022-2025 | Verquvo, Winrevair |
| E.R. Squibb & Sons, L.L.C. | $84.90 | 2023-2025 | Eliquis, Camzyos |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $80.35 | 2022 | |
| Bridgebio Pharma, INC. | $80.02 | 2025 | Attruby |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $72.18 | 2021-2025 | Lifevest |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $69.17 | 2024 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $40.57 | 2023-2024 | Uptravi, Opsumit |
| Novo Nordisk INC | $38.99 | 2023-2025 | Ozempic, Wegovy |
| Amarin Pharma, INC. | $23.09 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $18.36 | 2024 | Evkeeza |
| Lexicon Pharmaceuticals, INC. | $14.99 | 2024 | |
| Scpharmaceuticals INC. | $14.45 | 2025 | |
| Pfizer INC. | $14.18 | 2024 | |
| Kiniksa Pharmaceuticals, LTD. | $12.72 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Decker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.